Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.74 USD | +1.79% | +4.17% | -18.63% |
22/04 | Citigroup Starts Privia Health Group With Buy Rating, $25 Price Target | MT |
19/03 | Canaccord Genuity Adjusts Privia Health Group Price Target to $37 From $41, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- With an expected P/E ratio at 78.17 and 56.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.63% | 2.18B | C+ | ||
+13.70% | 81.68B | C+ | ||
-29.20% | 69.23B | B- | ||
+9.72% | 29.08B | C+ | ||
-11.43% | 16.88B | B | ||
-0.43% | 16.85B | A- | ||
-0.31% | 15.15B | A- | ||
+3.42% | 12.62B | A- | ||
+28.34% | 12.47B | B- | ||
-30.70% | 11.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PRVA Stock
- Ratings Privia Health Group, Inc.